Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by AGC Biologics

News headline image
AGC Biologics to Manufacture AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Disorders
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Seattle Facility Achieves Milestone Year with Regulatory Approvals, Customer Satisfaction and Zero-Finding ISO Certification Inspection
From AGC Biologics
Via Business Wire
News headline image
European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
From AGC Biologics
Via Business Wire
News headline image
From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Partners with Quell Therapeutics to Advance T-Regulatory Cell Therapies for Immune Disorders
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Partners with Novelty Nobility for Cell Line Development and Phase I Preparations of Antibody Drug Candidate
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Strengthens Single-Use Technology Network and Adds 5,000 L Vessels from Thermo Scientific to New Yokohama, Japan Facility
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Forms Dedicated “Cell and Gene Technologies Division,” Designed to Build Upon Their Track Record of Nine Commercially Approved Products to Date
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Honored by Customers and Industry Leaders for Excellence in Contract Development and Manufacturing
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms offering Flexible and Accelerated Vector Development and Manufacturing for Cell and Gene Therapy Programs
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Received Bioprocessing Excellence Award in Japan
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™
From AGC Biologics
Via Business Wire
News headline image
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
From AGC Biologics
Via GlobeNewswire
News headline image
AGC Biologics Honored for Innovations in Cell Line Development
From AGC Biologics
Via GlobeNewswire
News headline image
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
From AGC Biologics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.